An augmented passive immune therapy to treat fulminant bacterial infections

Recent Patents on Anti-Infective Drug Discovery

Volumn 5, Issue 2, 2010, Pages 157-167

  Rajam, Gowrisankar ^a   Sampson, Jacquelyn ^a   Carlone, George M ^a   Ades, Edwin W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antibody therapy; Bio molecule; Immune enhancement; P4 peptide; Passive immunization

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; AMINO ACID DERIVATIVE; BASILIXIMAB; BEVACIZUMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EFALIZUMAB; GANCICLOVIR; GEMTUZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OKT 3; OMALIZUMAB; P4 PEPTIDE; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; TOSITUMOMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BACTERIAL INFECTION; BLADDER CANCER; BREAST CANCER; CARDIOVASCULAR DISEASE; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; CROHN DISEASE; DENDRITIC CELL; GRAFT REJECTION; HUMAN; INNATE IMMUNITY; MACROPHAGE; MELANOMA; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; OPSONIZATION; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PASSIVE IMMUNIZATION; PATENT; PHARMACODYNAMICS; PNEUMOVIRUS INFECTION; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE TUMOR; PSORIASIS; RETINA MACULA DEGENERATION; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TREATMENT INDICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BACTERIAL INFECTIONS; HUMANS; IMMUNIZATION, PASSIVE; MODELS, IMMUNOLOGICAL; PATENTS AS TOPIC; PHAGOCYTOSIS;

EID: 77954065219     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489110791233496     Document Type: Article

References (136)

1. Burton DR, Saphire EO, Parren PW. A model for neutralization of viruses based on antibody coating of the virion surface. Curr Top Microbiol Immunol 2001; 260: 109-43.
2. Parren PW, Burton DR. The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 2001; 77: 195-262.
3. Buchwald UK, Pirofski L. Immune therapy for infectious diseases at the dawn of the 21st century: The past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. Curr Pharm Des 2003; 9: 945-68.
4. Winau F, Winau R. Emil von Behring and serum therapy. Microbes Infect 2002; 4: 185-8.
5. Casadevall A, Scharff MD. Serum therapy revisited: Animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 1994; 38: 1695-702.
6. Casadevall A, Scharff MD. Return to the past: The case for antibody-based therapies in infectious diseases. Clin Infect Dis 1995; 21: 150-61.
7. Grundbacher FJ. Behring's discovery of diphtheria and tetanus antitoxins. Immunol Today 1992; 13: 188-90.
8. Weisse ME. The fourth disease, 1900-2000. Lancet 2001; 357: 299-301.
9. Casadevall A. Antibody-based therapies as anti-infective agents. Expert Opin Investig Drugs 1998; 7: 307-21.
10. Glatman-Freedman A, Casadevall A. Serum therapy for tuberculosis revisited: Reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev 1998; 11: 514-32.
11. Bregenholt S, Haurum J. Pathogen-specific recombinant human polyclonal antibodies: Biodefence applications. Expert Opin Biol Ther 2004; 4: 387-96.
12. Pennington JE. Newer uses of intravenous immunoglobulins as anti-infective agents. Antimicrob Agents Chemother 1990; 34: 1463-6.
13. Pasatiempo AM, Kroser JA, Rudnick M, Hoffman BI. Acute renal failure after intravenous immunoglobulin therapy. J Rheumatol 1994; 21: 347-9.
14. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors. Ann Intern Med 1994; 121: 259-62.
15. Casadevall A. Crisis in infectious diseases: Time for a new paradigm? Clin Infect Dis 1996; 23: 790-4.
16. Casadevall A. Passive antibody therapies: Progress and continuing challenges. Clin Immunol 1999; 93: 5-15.
17. Casadevall A, Dadachova E, Pirofski LA. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004; 2: 695-703.
18. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7.
19. Krause RM, Dimmock NJ, Morens DM. Summary of antibody workshop: The role of humoral immunity in the treatment and prevention of emerging and extant infectious diseases. J Infect Dis 1997; 176: 549-59.
20. Bullowa JG. Pneumonias: Their management. Cal West Med 1937; 46: 368-72.
21. Buelow R, van Schooten W. The future of antibody therapy. Ernst Schering Found Symp Proc 2006: 83-106.
22. Kang AS, Jones TM, Burton DR. Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. Proc Natl Acad Sci USA 1991; 88: 11120-3.
23. Green LL, Hardy MC, Maynard-Currie CE, Tsuda H, Louie DM, Mendez MJ, et al. Antigen-specific human monoclonal antibodies from mice engineered with human IG heavy and light chain YACs. Nat Genet 1994; 7: 13-21.
24. Sharon J, Sarantopoulos S, Den W, Kao CY, Baecher-Allan CM, Santora KE, et al. Recombinant polyclonal antibody libraries. Comb Chem High Throughput Screen 2000; 3: 185-96.
25. Sharon M, Gorlach M, Levy R, Hayek Y, Anglister J. Expression, purification, and isotope labeling of a gp120 V3 peptide and production of a Fab from a HIV-1 neutralizing antibody for NMR studies. Protein Expr Purif 2002; 24: 374-83.
26. Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 2007; 25: 1421- 34.
27. Heinzel FP. Antibodies. In: Mandell GL, Bennett JE, Dolin R, Eds. Principles and practice of infectious diseases. New York: Churchill Linvingstone 1995; 36-57.
28. Pai JC, Sutherland JN, Maynard JA. Progress towards recombinant anti-infective antibodies. Recent Pat Antiinfect Drug Discov 2009; 4: 1-17.
29. Church AC. Clinical advances in therapies targeting the interleukin-2 receptor. QJM 2003; 96: 91-102.
30. Finckh A, Simard JF, Duryea J, Liang MH, Huang J, Daneel S, et al. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: A population-based study. Arthritis Rheum 2006; 54: 54-9.
31. Alexander HR, Jr, Fraker DL, Bartlett DL, Libutti SK, Steinberg SM, Soriano P, et al. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol 2010; 28(1): 114-8.
32. Li YG, Wang ZP, Tian JQ, Tian BQ, Rodrigues R, Shang PF, et al. Dendritic cell transfected with secondary lymphoid-tissue chemokine and/or interleukin-2 gene-enhanced cytotoxicity of tlymphocyte in human bladder tumor cells in vitro. Cancer Invest 2010; 27(9): 909-17.
33. Siddiqui K, Klotz LH. Emerging drugs for prostate cancer. Expert Opin Emerg Drugs 2009; 14: 455-70.
34. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-8.
35. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-7.
36. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59. Blood 2001; 98: 3383-9.
37. Mina L, Sledge GW, Jr. Twenty years of systemic therapy for breast cancer. Oncology (Williston Park) 2006; 20: 25-32.
38. Casadevall A, Pirofski LA. New concepts in antibody-mediated immunity. Infect Immun 2004; 72: 6191-6.
39. Foster JK, Verdile G, Bates KA, Martins RN. Immunization in Alzheimer's disease: Naive hope or realistic clinical potential? Mol Psychiatry 2009; 14: 239-51.
40. Gentry WB, Ruedi-Bettschen D, Owens SM. Development of active and passive human vaccines to treat methamphetamine addiction. Hum Vaccine 2009; 5: 206-13.
41. Baillie JK, Power I. The mechanism of action of gabapentin in neuropathic pain. Curr Opin Investig Drugs 2006; 7: 33-9.
42. Brachman PS. Infectious diseases-past, present, and future. Int J Epidemiol 2003; 32: 684-6.
43. Grabenstein JD. Vaccines: Countering anthrax: Vaccines and immunoglobulins. Clin Infect Dis 2008; 46: 129-36.
44. Walsh JJ, Pesik N, Quinn CP, Urdaneta V, Dykewicz CA, Boyer AE, et al. A case of naturally acquired inhalation anthrax: Clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis 2007; 44: 968-71.
45. Morrow MP, Weiner DB. Cytokines as adjuvants for improving anti-HIV responses. AIDS 2008; 22: 333-8.
46. Harvey, B.R., Georgiou, G., Iverson, B.L. Antibodies with increased affinities for anthrax antigens. US20086916474 (2008).
47. McGuinness AC, Armstrong JG, Felton HM. Hyperimmune whopping cough serum. J Paediatr 1944; 24: 249-58.
48. Ballow M. Clinical and investigational considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005; 62: S12-8-S9-21.
49. Blake PA, Feldman RA, Buchanan TM, Brooks GF, Bennett JV. Serologic therapy of tetanus in the United States, 1965-1971. JAMA 1976; 235: 42-4.
50. Orth D, Grif K, Zimmerhackl LB, Wurzner R. Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans. Expert Rev Anti Infect Ther 2008; 6: 101-8.
51. Younson J, O'Mahony R, Liu H, Grant S, Campion C, Jennings L, et al. A human domain antibody and Lewis b glycoconjugate that inhibit binding of Helicobacter pylori to Lewis b receptor and adhesion to human gastric epithelium. J Infect Dis 2009; 200: 1574-82.
52. Moriyama K, Wiener-Kronish JP, Sawa T. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice. Microbiol Immunol 2009; 53: 587-94.
53. Rajam G, Carlone GM, Romero-Steiner S. Functional antibodies to the O-acetylated pneumococcal serotype 15B capsular polysaccharide has low cross-reactivities with serotype 15C. Clin Vaccine Immunol 2007; 14: 1223-7.
54. Smith DJ, Mattos-Graner RO. Secretory immunity following mutans streptococcal infection or immunization. Curr Top Microbiol Immunol 2008; 319: 131-56.
55. Schaffer AC, Lee JC. Vaccination and passive immunisation against Staphylococcus aureus. Int J Antimicrob Agents 2008; 32: S71-8.
56. Patti, J.M., Foster, T.J., Hook, M. Staphylococcal immunotherapeutics via donor selection and donor stimulation. US20086692739 (2008).
57. Horwith, G., Fattom, A.I. Method of treating Staphylococcus aureus infection. US20060153857 (2006).
58. Burnie, J.P., Matthews, R.C. Treatment of microorganism infection. US20070202116 (2007).
59. Patti, J.M., Hutchins, J.T., Domanski, P., Patel, P., Hall, A. Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections. US6979446 (2005).
60. Stinson, J.R., Schuman, R.F., Mond, J.J., Lees, A., Fischer, G.W. US20080019976 (2008).
61. Palladino G, Mozdzanowska K, Washko G, Gerhard W. Virusneutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 1995; 69: 2075-81.
62. Lu J, Guo Z, Pan X, Wang G, Zhang D, Li Y, et al. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Respir Res 2006; 7: 43.
63. Prabhu N, Prabakaran M, Hongliang Q, He F, Ho HT, Qiang J, et al. Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza. Antivir Ther 2009; 14: 911-21.
64. Prabhu N, Prabakaran M, Ho HT, Velumani S, Qiang J, Goutama M, et al. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J Virol 2009; 83: 2553-62.
65. Manikkavasagan G, Ramsay M. Protecting infants against measles in England and Wales: A review. Arch Dis Child 2009; 94: 681-5.
66. Tebruegge M, Pantazidou A, Curtis N. Towards evidence based medicine for paediatricians. How effective is varicella-zoster immunoglobulin (VZIG) in preventing chickenpox in neonates following perinatal exposure? Arch Dis Child 2009; 94: 559-61.
67. Opriessnig T, Patterson AR, Madson DM, Pal N, Ramamoorthy S, Meng XJ, et al. Comparison of the effectiveness of passive (dam) versus active (piglet) immunization against porcine circovirus type 2 (PCV2) and impact of passively derived PCV2 vaccine-induced immunity on vaccination. Vet Microbiol 2009 [Epub ahead of print].
68. Zolla-Pazner S, Gorny MK. Passive immunization for the prevention and treatment of HIV infection. AIDS 1992; 6: 1235-47.
69. Cavacini LA, Samore MH, Gambertoglio J, Jackson B, Duval M, Wisnewski A, et al. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res Hum Retroviruses 1998; 14: 545-50.
70. Cavacini LA, Emes CL, Wisnewski AV, Power J, Lewis G, Montefiori D, et al. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res Hum Retroviruses 1998; 14: 1271-80.
71. Holl V, Peressin M, Decoville T, Schmidt S, Zolla-Pazner S, Aubertin AM, et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J Virol 2006; 80: 6177-81.
72. Holl V, Peressin M, Schmidt S, Decoville T, Zolla-Pazner S, Aubertin AM, et al. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti- HIV-1 IgG without induction of maturation. Blood 2006; 107: 4466-74.
73. Fung, S.C. Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome. US20060121480 (2006).
74. Kramer VG, Siddappa NB, Ruprecht RM. Passive immunization as tool to identify protective HIV-1 Env epitopes. Curr HIV Res 2007; 5: 642-55.
75. West AP, Jr., Galimidi RP, Foglesong CP, Gnanapragasam PN, Huey-Tubman KE, Klein JS, et al. Design and expression of a dimeric form of human immunodeficiency virus type 1 antibody 2G12 with increased neutralization potency. J Virol 2009; 83: 98-104.
76. Thorpe, P.E., Soares, M.M., Ran, S. Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids. US7455833 (2008).
77. Ostberg, L.G. Human monoclonal antibodies to cytomegalovirus US5750106 (2008).
78. Zimmermann J, Saalbach I, Jahn D, Giersberg M, Haehnel S, Wedel J, et al. Antibody expressing pea seeds as fodder for prevention of gastrointestinal parasitic infections in chickens. BMC Biotechnol 2009; 9: 79.
79. Margolis AR, Grabenstein JD. Immunizations against bioterrorism: Smallpox and anthrax. J Am Pharm Assoc (2003) 2009; 49: 566-8.
80. de la Morena MT. Specific immune globulin therapy for prevention of nosocomial staphylococcal bloodstream infection in premature infants: Not what we hoped for! J Pediatr 2007; 151: 232-4.
81. Shah PS, Kaufman DA. Antistaphylococcal immunoglobulins to prevent staphylococcal infection in very low birth weight infants. Cochrane Database Syst Rev 2009: CD006449.
82. Fink MP. Adoptive immune therapy of gram-negative sepsis: Use of monoclonal antibodies to lipopolysaccharide. Crit Care Med 1994; 21: 32-9.
83. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, et al. Structural definition of a conserved neutralization epitope on HIV- 1 gp120. Nature 2007; 445: 732-7.
84. Law M, Hangartner L. Antibodies against viruses: Passive and active immunization. Curr Opin Immunol 2008; 20: 486-92.
85. Nascimento RC, Espindola NM, Castro RA, Teixeira PA, Penha LCV, Lopes-Bezerra LM, et al. Passive immunization with monoclonal antibody against a 70-kDa putative adhesin of Sporothrix schenckii induces protection in murine sporotrichosis. Eur J Immunol 2008; 38: 3080-9.
86. Casadevall A. Antibody-mediated immunity against intracellular pathogens: Two-dimensional thinking comes full circle. Infect Immun 2003; 71: 4225-8.
87. Waldmann TA. Immunotherapy: Past, present and future. Nat Med 2003; 9: 269-77.
88. Beeler JA, van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: Effect of mutation upon fusion function. J Virol 1989; 63: 2941-50.
89. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23: 1073-8.
90. Rajam G, Skinner J, Melnick N, Martinez J, Carlone GM, Sampson JS, et al. A 28-aa pneumococcal surface adhesin A-derived peptide, P4, augments passive immunotherapy and rescues mice from fatal pneumococcal infection. J Infect Dis 2009; 199: 1233-8.
91. Kim JO, Romero-Steiner S, Sorensen UB, Blom J, Carvalho M, Barnard S, et al. Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae. Infect Immun 1999; 67: 2327-33.
92. Rajam G, Phillips DJ, White E, Anderton J, Hooper CW, Sampson JS, et al. A functional epitope of the pneumococcal surface adhesin A activates nasopharyngeal cells and increases bacterial internalization. Microb Pathog 2008; 44: 186-96.
93. Anderton JM, Rajam G, Romero-Steiner S, Summer S, Kowalczyk AP, Carlone GM, et al. E-cadherin is a receptor for the common protein pneumococcal surface adhesin A (PsaA) of Streptococcus pneumoniae. Microb Pathog 2007; 42: 225-36.
94. Ades, E.W., Sampson, J.S., Steiner, S., Carlone, G.M., Caba, J.J., Rajam, G. Functional epitopes of Streptococcus pneumoniae PsaA antigen and uses thereof. US11992719A1 (2009).
95. Melnick N, Rajam G, Carlone GM, Sampson JS, Ades EW. Evaluation of a novel therapeutic approach to treating severe pneumococcal infection using a mouse model. Clin Vaccine Immunol 2009; 16: 806-10.
96. Keler, T., Lowy, I., Vitale, L.A., Blanset, D., Srinivasan, M. Human monoclonal antibodies against Bacillus anthracis protective antigen. US20087456264 (2008).
97. Morrow, P.R., Kang, A.S., Wang, F., Jiang, I., Sawada, R., Scholz, W.l. Passive immunization and methods of treament for anthrax using antibodies. US20080081042 (2008).
98. Ambrosino, D., Babcock, G.J., Broering, T., Graziano, R., Hernandez, H.J., Lowy, I., Mandell, R., Molrine, D., Thomas, W.D., Zhang, H.F. Antibodies against Clostridium difficile toxins and uses thereof. US20050287150 (2005).
99. Smith, M., Melton-Celsa, A., O'brien, A. Methods and compositions based on Shiga toxin type 1 protein. US20070292426 (2007).
100. Makler, O., Reiter, Y. Methods of diagnosing and treating cytomegalovirus diseases.WO2008120203 (2008).
101. Xia, N., Chen, Y., Ge, S., Luo,W., Zhang, J. Monoclonal antibodies binding to avian influenza virus subtype H5 haemagglutinin and uses thereof. WO2007089753 (2007).
102. Fern, H.Y., Yun, D.Q., Fang, H. H5 subtype-specific binding proteins useful for h5 avian influenza diagnosis and surveillance. WO2008140415 (2008).
103. Van Den, B.E.N., De Kruif, C.A., Throsby, M. Human binding molecules capable of neutralizing influenza virus H5N1 and uses thereof. WO2008028946 (2008).
104. Broering, T., Sloan, S., Babcock, G.J., Ambrosin, D., Thomas, W.D. Human antibodies against hepatitis C virus (HCV) uses thereof. WO2008108918 (2008).
105. Nagashima, K., Olson, W.C., Maddon, P.J., Koduri, R., Donovan, G.P., Tsurushita, N., Tso, J., Kumar, S. Monoclonal antibodies that potently neutralize hepatitis C virus (HCV) of diverse genotypes. WO2007143701 (2007).
106. Olson, W.C., Maddon, P.J., Pevear, D.C., Israel, R.J., Murga, J.D. Methods for reducing viral load in HIV-1-infected patients. WO2007014114 (2007).
107. Kuhne, M., Brams, P., Tanamachi, D.M., Korman, A., Cardarrelli, J.M. Human antibodies that bind cxcr4 and uses thereof. WO2008060367 (2008).
108. Arthos, J., Goode, D., Cicala, C., Fauci, A. Use of antagonists of the interaction between HIV gp120 and a4ss7 integrin. WO2008140602 (2008).
109. Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, et al. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci USA 2002; 99: 6913-8.
110. Choudhry V, Zhang MY, Dimitrova D, Prabakaran P, Dimitrov AS, Fouts TR, et al. Antibody-based inhibitors of HIV infection. Expert Opin Biol Ther 2006; 6: 523-31.
111. Brams, P., Morrow, P.R. Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof. US20070082002 (2007).
112. Prince, G., Johnson, L.S. Combination therapy of respiratory diseases using antibodies and anti-inflammatory agents. US20070224204 (2007).
113. Marasco, W., Sui, J. Antibodies against SARS-CoV and methods of use thereof. WO2007044695 (2007).
114. Ambrosino, D., Babcock, G.J., Broering, T., Graziano, R., Hernandez, H.J., Lowy, I., Mandell, R., Molrine, D., Thomas, W.D., Zhang, H.F. SARS nucleic acids, proteins, antibodies, and uses thereof. US20050069869 (2005).
115. Ter Meulen, J.H., Van Den, B.E.N., De Kruif, C.A., Goudsmit, J. Compositions against SARS-coronavirus and uses thereof. WO2006051091 (2006).
116. Jiang, S., He, Y. Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus. US20060240551 (2006).
117. Babcook, J.S., Prabhakar, B.S., Coughlin, M. Interleukin-13 antibody composition. US20080248048 (2008).
118. ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, et al. Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants. PLoS Med 2006; 3: e237.
119. Kinet, J.P., Jouvin, M.H. Smallpox monoclonal antibody. WO2008085551 (2008).
120. Yamamoto, S., Bower, D.J., Furuya, H., Yanase, H., Sargeant, S.J. WO2008011295915 (2008).
121. Chen, Z., Earl, P., Moss, B., Emerson, S.U., Purcell, R.H. Monoclonal antibodies against orthopoxviruses. WO2007075915 (2007).
122. Rasmussen, L.K., Frandsen, T., Rasmussen, S.K., Andersen, P.S. A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line. WO2006007853 (2006).
123. Jensen, A., Lantto, J., Hansen, M.H., Rasmussen, L.K., Rasmussen, S.K., Steinaa, L. Anti-orthopoxvirus recombinant polyclonal antibody. US20080069822 (2008).
124. Throsby, M., De Kruif, C.A. Binding molecules capable of neutralizing West Nile virus and uses thereof. US20077244430 (2007).
125. Bavari, S., Melendez, E.R., Lebeda, F.J. Antibodies against type A botulinum neurotoxin. US20060177881 (2006).
126. Marks, J.D., Amersdorfer, P., Geren, I., Lou, J., Razai, A., Garcia, M.C. Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins. US20080124328 (2008).
127. Thomas, W.D., Giannasca, P.J., Zhang, Z., Lei, W., Monath, T.P. Immunization against Clostridium difficile disease. US20060029608 (2006).
128. Tzipori, S., Balakrishnan, R., Donohue-rolfe, A. humanized neutralizing antibodies against hemolytic uremic syndrome. US20080107651 (2008).
129. Mohamed, N., Spitalny, G.L., Casey, L.S., Jones, S.M., Pincus, S.E. Use of CR1-binding molecules in clearance and induction of immune responses. US20060263792 (2006).
130. Dadachova, E., Casadevall, A., Nakouzi, A. Methods of applying ionization radiation for therapy of infections. US20040115203 (2004).
131. Burnie, J.P., Matthews, R.C. Treatment of fungal infections. US20080095778 (2008).
132. Charlton, K.A., Porter, A.J.R. Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody. US20060165704 (2006).
133. Frey, J., Stuber, K., Thornton, J.C., Kuzyk, M.A., Burian, J. Type III secretion pathway in aeromonas salmonicida, and uses therefor. US20087232569 (2008).
134. Hill, J., Williamson, E.D., Titball, R.W.L. Vaccine against yersinia comprising one or two antibodies, one specific for Yersinia pestis F1-antigen and the other one for Yersinia pestis v-antigen. US20060093609 (2006).
135. Gilbert DN. Scenario 1: A patient with mild community-acquired pneumonia-introduction to clinical trial design issues. Clin Infect Dis 2008; 47 (Suppl 3): S121-2.
136. Le Page L, Lecaque C, Guerin D, Picard A, Lion-Daolio S, Grignon P, et al. A psoas abscess. Rev Med Int 2008; 29: 406-7.